Fairvoy Private Wealth LLC Takes Position in AstraZeneca PLC (NASDAQ:AZN)

Fairvoy Private Wealth LLC purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, Holdings Channel reports. The fund purchased 4,606 shares of the company’s stock, valued at approximately $302,000.

Other hedge funds have also added to or reduced their stakes in the company. Stratos Wealth Advisors LLC grew its holdings in AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares during the period. Crumly & Associates Inc. raised its holdings in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after purchasing an additional 143 shares during the period. Diversify Wealth Management LLC boosted its position in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares in the last quarter. Veery Capital LLC grew its holdings in shares of AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares during the period. Finally, Harbour Investments Inc. increased its position in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after buying an additional 160 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN opened at $71.99 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a market capitalization of $223.25 billion, a P/E ratio of 31.85, a P/E/G ratio of 1.20 and a beta of 0.46. The company has a 50 day moving average of $67.38 and a 200-day moving average of $73.69.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.55%. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.66 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be paid a dividend of $1.03 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a dividend yield of 2%. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s dividend payout ratio is currently 43.36%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.